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 ABSTRACT |	 Residual	cyst	is	an	inflammatory	odontogenic	cyst	resultant	from	pulp	necrosis,	where	the	tooth	has	already	been	re-





 DESCRIPTORS |	 Bisphosphonates;	Osteonecrosis;	Cysts.
 RESUMO | Excisão cirúrgica de cisto residual em um paciente com história prévia de osteonecrose associada ao uso de bisfosfonato: 





 DESCRITORES |	 Bisfosfonatos;	Osteonecrose;	Cistos.
 CORRESPONDING AUTHOR | • Ana Carolina Uchoa Vasconcelos Serviço de Patologia Bucal, Universidade Federal de 
Pelotas  • Rua Gonçalves Chaves, 457, sala 607, Centro Pelotas, RS, Brazil  • 96015-
560 E-mail: carolinauv@gmail.com




192 ● Clin Lab Res Den 2015; 21 (3): 191-196
INTRODUCTION
Bisphosphonates	are	a	group	of	drugs	that	have	
been	 used	 in	 the	 management	 of	 metabolic	 and	
oncologic	diseases	characterized	by	an	increase	of	
osteoclastic	 activity.	 In	 the	 clinical	 setting,	 these	










proved	 parenteral	 administration	 of	 zoledronic	
acid	for	management	of	osteoporosis.1
Adverse	 effects	 of	 bisphosphonate	 therapy	 are	
intimately	 related	 to	 type,	 frequency	 and	 route	 of	
drug	 administration.	 Firstly	 described	 in	 2003,	
bisphosphonate-related	 osteonecrosis	 of	 the	 jaws	
(BRONJ),	 now	 called	 medication-related	 osteo-
necrosis	of	 the	 jaw	(MRONJ)	 is	an	 important	side	
effect	 whose	 etiopathogenesis	 is	 not	 complete-
ly	known.2	 It	was	estimated	 that	up	 to	 12%	of	pa-
tients	 treated	with	 IV	 bisphosphonates	 for	 cancer	







had	 radiation	 therapy	 to	 the	 craniofacial	 region.3 
Radiographic	 features	 cannot	 be	 distinguished	
from	 periapical	 lesions,	 osteomyelitis,	 primary	 or	
metastatic	 bone	 disease.4	 Microscopically,	 non-
-vital	bone	tissue,	chronic	 inflammatory	 infiltrate,	
bacteria	 colonization	 consistent	with	Actinomyces	
sp,	 and	 absence	 of	 osteoclasts	 are	 observed.	
Furthermore,	 intertrabecular	 fibrosis	 and	 inflam-
matory	 infiltrate	 within	 bone	marrow	 spaces	 can	
also	be	noted.5
The	 major	 goal	 of	 management	 for	 patients	
who	have	MRONJ	 is	 to	preserve	 the	quality	of	 life	
through	 controlling	 pain,	managing	 infection,	 and	
preventing	 the	development	of	new	areas	of	necro-
sis.4	Laboratory	tests	that	can	provide	the	intensity	
of	 collagen	 degradation,	 such	 as	 carboxy-terminal	
collagen	 crosslinks	 (CTX),	 even	 nonspecific,	 can	
provide	predictive	values	in	cases	that	need	maxillo-
facial	surgery.6 






MRONJ	 in	 right	 mandible	 two	 months	 after	 ex-
traction	of	right	mandibular	first	and	second	pre-






microbial	 solutions	 (erythromycin,	 chlorhexidine	
and	 hydrogen	 peroxide).	 During	 routine	 exami-
nations,	 three	years	 after	 extractions,	panoramic	
radiograph	revealed	a	well-circumscribed	and	ra-
diolucent	lesion,	measuring	2.3x1.7	cm,	in	the	pos-
terior	 left	 side	 of	maxilla	 (Figure	 1)	 without	 any	
clinical	 sign	and	compatible	with	a	 residual	 cyst.	
Computed	tomography	showed	a	well	demarcated,	
unilocular	 and	 hypodense	 mass	 in	 the	 posterior	
left	side	of	maxilla,	measuring	1.3x1.1	cm	(Figure	
2).	 At	 this	 point,	 patient	 was	 not	 using	 bisphos-
phonate	anymore	(for	about	six	months)	but	CTX	
was	still	low.
Vasconcelos ACU • Borges WD •Heitz C • Salum FG • Figueiredo MAZ • Nascimento GG • Duarte AAPS • Cherubini K
Clin Lab Res Den 2015; 21 (3): 191-196 ●  193
Figure 1 | Initial panoramic radiography.
Figure 2 | Initial computed tomography.
Surgical	 excision	 of	 the	 cystic	 lesion	 was	 in-
dicated	 only	 when	 CTX	 improvement	 was	 obser-
ved.	Hematologic	exams	 including	complete	blood	
count,	 prothrombin	 time,	 activated	 thromboplas-
tin	 time,	 aspartate	 transaminase	 (AST),	 alanine	
transaminase	 (ALT),	 urea	 and	 fasting	 blood	 glu-
cose	(FBG)	showed	normal	results.	Also,	CTX	was	
requested	 again,	 and	 the	 result	 was	 430	 pg/mL,	
which	 would	 represent	minimal	 risk	 for	MRONJ,	
according	to	Marx.6
During	 surgical	 procedure,	 intra-	 and	 extra-
-oral	antisepsis	was	made	with	chlorhexidine,	and	
local	anesthesia	was	performed	with	mepivacaine.	
Tissue	 incision	 and	 divulsion	 were	 performed	 on	
a	 minimally	 traumatic	 technique.	 A	 Lucas	 curet-
te	 was	 used	 to	 displace	 the	 cyst	 capsule	 and,	 af-
ter	 lesion	 excision,	 the	 affected	 site	 was	 irrigated	
with	 physiological	 saline	 solution,	 with	 posterior	
osteoplasty	 and	 continuous	 suture	 with	 nylon	 (4-
0).	 After	 surgical	 procedure,	 the	 patient	 received	
a	 prescription	 of	 oral	 clindamycin,	 300mg,	 for	 7	
days;	 oral	 nimesulide,	 100mg,	 for	 3	 days,	 sublin-
gual	trometamol,	10	mg,	for	3	days	and	mouthrinse	
with	0.12%	chlorhexidine.
Histopathological	 examination	 revealed	 an	
inflammatory	 cyst,	 lined	 with	 stratified	 squa-
mous	 epithelium,	 which	 showed	 hydropic	 dege-
neration,	 spongiosis	 and	hyperplastic	 areas.	The	
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connective	 tissue	 was	 fibrous	 with	 small	 caliber	
blood	 vessels,	 presenting	 predominantly	 mono-
nuclear	 inflammatory	 infiltrate	(Figure	3).	These	
characteristics	 confirmed	 the	 radiographic	 diag-
nosis	 of	 residual	 cyst.	 Follow-up	 appointments	
were	booked	weekly	 in	 the	first	 two	months	and	
periapical	surgery	are	considered	local	risk	factors	
for	this	condition.7	Duration	of	treatment,	as	well	as	
bisphosphonate	 type	 and	 route	 of	 administration	
can	also	be	included	as	risk	factors.	Although	the-
re	 is	no	 scientific	 evidence,	 diabetes,	 obesity,	 coa-
gulopathies,	anemia,	use	of	alcohol	and	tobacco	are	
pointed	out	as	possible	predisposing	factors.7





after	 the	 surgical	 procedure,	 the	 patient	 showed	
normal	healing	of	the	surgical	wound	without	any	
sign	 of	 MRONJ	 (Figure	 5),	 and	 she	 is	 currently	
under	follow-up.
DISCUSSION
MRONJ	 is	 reported	as	an	 important	 complica-
tion	of	bisphosphonate	 therapy	especially	associa-
ted	with	 the	 use	 of	 aminobisphosphonates,	which	
is	 difficult	 to	 treat	 and	 can	 considerably	 impair	
the	 patient’s	 quality	 of	 life.	 Periodontal	 disease,	
tooth	 extractions,	 dental	 implants	 placement,	 and	
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Many	 hypotheses	 have	 been	 postula-
ted	 to	 explain	 the	 pathogenesis	 of	 MRONJ.	
Bisphosphonates	are	able	 to	 interfere	with	remo-
deling	of	bone	tissue	by	acting	on	different	cells.8,9 
Their	 effect	 on	 osteoclasts	 occurs	 by	 inhibiting	
recruitment	 and	 differentiation,	 decreasing	 life	




genesis	 and	 epithelial	 cell	 proliferation,9	 support	
the	hypothesis	that	osteonecrosis	of	the	jaws	has	a	
multifactorial	etiology.	





American	 Association	 of	 Oral	 and	 Maxillofacial	
Surgeons	 (AAOMS)	 recommends	 that	 patients	
in	 use	 of	 oral	 bisphosphonates	 for	 three	 years	 or	
longer	 and	 using	 corticosteroids	 simultaneously	




It	 is	 important	 to	 highlight	 that	 the	 reported	
patient	 was	 successfully	 subjected	 to	 a	 surgical	





was	20	pg/mL	(high	risk	 for	MRONJ)	at	 the	 time	
patient	 developed	 MRONJ,	 and	 had	 increased	 to	
430	pg/mL	(minimal	risk)6	at	the	time	surgery	was	
performed.	Hence,	CTX	in	this	case	was	a	helpful	





development	of	MRONJ,	 it	 is	probably	not	 the	pri-











tinued	 for	 17	days.	Although	 there	 is	no	consensus	
in	the	literature	about	this	protocol,	penicillin	is	the	
antibiotic	of	choice	for	prophylactic	and	post	opera-
tory	use	 in	oral	surgery	 in	patients	at	 risk	of	deve-
loping	MRONJ.6,10	In	this	case	it	was	not	prescribed	
amoxicillin	before	the	surgical	procedure.
We	 have	 reported	 here	 a	 well-succeeded	 sur-
gical	 excision	 of	 a	 residual	 cyst	 in	 a	 patient	 who	
had	previously	developed	MRONJ	associated	with	
sodium	 alendronate	 use.	 Despite	 the	 evidence	 of	
the	risks,	maxillofacial	surgeries	are	often	deman-
ded	 by	 patients	 under	 bisphosphonate	 therapy.	
Moreover,	 although	 rare,	MRONJ	 associated	with	
oral	 bisphosphonate	 does	 happen.	 Therefore,	 the	
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Maxillofacial	 Surgeons	 position	 paper	 on	medication-
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